Stock 4595 MIZUHO MEDY CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mizuho Medy Co.,Ltd.

Equities

4595

JP3885900005

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,305 JPY -0.45% Intraday chart for Mizuho Medy Co.,Ltd. +2.01% +5.25%
2021 Mizuho Medy Co.,Ltd.(TSE:4595) added to S&P Global BMI Index CI
2020 Mizuho Medy Co.,Ltd.(TSE:4595) dropped from S&P Global BMI Index CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 26,764 12,249 22,459 35,717 29,907 31,478 - -
Enterprise Value (EV) 1 27,224 12,787 18,133 27,015 19,773 20,008 19,041 17,928
P/E ratio 30.6 x 40 x 4.66 x 4.56 x 7.92 x 11.9 x 11.1 x 10.5 x
Yield 1.03% 0.78% 6.57% 6.67% 6.37% 4.24% 4.54% 4.84%
Capitalization / Revenue 4.16 x 2.91 x 1.71 x 2.03 x 2.72 x 3.31 x 3.15 x 3 x
EV / Revenue 4.24 x 3.04 x 1.38 x 1.54 x 1.8 x 2.11 x 1.9 x 1.71 x
EV / EBITDA 21.3 x 21 x 2.64 x - - 5.07 x 4.53 x 3.94 x
EV / FCF -939 x 71.8 x 3.33 x - 5.34 x 7.56 x 8.02 x 6.86 x
FCF Yield -0.11% 1.39% 30% - 18.7% 13.2% 12.5% 14.6%
Price to Book 7.13 x 3.24 x 2.8 x 2.5 x 1.91 x 1.85 x 1.71 x 1.58 x
Nbr of stocks (in thousands) 9,525 9,525 9,524 9,524 9,524 9,524 - -
Reference price 2 2,810 1,286 2,358 3,750 3,140 3,305 3,305 3,305
Announcement Date 2/12/20 2/10/21 2/10/22 2/10/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,427 4,205 13,137 17,581 10,989 9,500 10,000 10,500
EBITDA 1 1,277 607.8 6,871 - - 3,950 4,200 4,550
EBIT 1 1,111 416 6,698 11,104 5,151 3,650 3,900 4,150
Operating Margin 17.29% 9.89% 50.99% 63.16% 46.87% 38.42% 39% 39.52%
Earnings before Tax (EBT) 1 1,170 415.2 6,824 11,070 5,292 3,650 3,900 4,150
Net income 1 874 306 4,816 7,838 3,774 2,650 2,830 3,010
Net margin 13.6% 7.28% 36.66% 44.58% 34.34% 27.89% 28.3% 28.67%
EPS 2 91.80 32.16 505.7 822.9 396.3 278.2 297.1 316.0
Free Cash Flow 1 -29 178 5,442 - 3,703 2,647 2,373 2,615
FCF margin -0.45% 4.23% 41.42% - 33.7% 27.86% 23.73% 24.9%
FCF Conversion (EBITDA) - 29.29% 79.2% - - 67.01% 56.5% 57.47%
FCF Conversion (Net income) - 58.17% 113% - 98.12% 99.89% 83.85% 86.88%
Dividend per Share 2 29.00 10.00 155.0 250.0 200.0 140.0 150.0 160.0
Announcement Date 2/12/20 2/10/21 2/10/22 2/10/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 1,663 6,353 4,223 2,561 4,188 3,125 7,313 5,968 4,300 2,391 2,184 4,575 3,415 2,999 2,900 1,900 4,800 2,100 2,600
EBITDA - - - - - - - - - - - - - - - - - - -
EBIT 1 -129 3,124 2,545 1,029 2,743 1,832 4,575 4,121 2,408 1,027 876 1,903 1,886 1,362 1,380 580 1,960 650 1,040
Operating Margin -7.76% 49.17% 60.27% 40.18% 65.5% 58.62% 62.56% 69.05% 56% 42.95% 40.11% 41.6% 55.23% 45.42% 47.59% 30.53% 40.83% 30.95% 40%
Earnings before Tax (EBT) 1 -129 3,220 2,574 1,030 2,748 1,832 4,580 4,193 2,297 1,050 1,003 2,053 1,942 1,297 1,380 580 1,960 650 1,040
Net income 1 -93 2,296 1,785 735 1,917 1,286 3,203 2,929 1,706 746 715 1,461 1,366 947 993 417 1,411 468 770
Net margin -5.59% 36.14% 42.27% 28.7% 45.77% 41.15% 43.8% 49.08% 39.67% 31.2% 32.74% 31.93% 40% 31.58% 34.24% 21.95% 29.4% 22.29% 29.62%
EPS -9.840 241.1 187.4 - 201.3 - 336.4 307.5 - 78.37 - 153.4 143.4 - - - - - -
Dividend per Share - 50.00 - - - - 60.00 - - - - 60.00 - - - - - - -
Announcement Date 8/11/20 8/10/21 11/8/21 2/10/22 5/9/22 8/10/22 8/10/22 11/11/22 2/10/23 5/12/23 8/10/23 8/10/23 11/10/23 2/9/24 - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 460 538 - - - - - -
Net Cash position 1 - - 4,326 8,702 10,134 11,470 12,437 13,550
Leverage (Debt/EBITDA) 0.3602 x 0.8852 x - - - - - -
Free Cash Flow 1 -29 178 5,442 - 3,703 2,647 2,373 2,615
ROE (net income / shareholders' equity) 25.3% 8.1% 81.6% 70.3% 25.2% 16.2% 16% 15.7%
ROA (Net income/ Total Assets) 18.6% 6.68% 73.5% 70.7% 27.8% 18.6% 18.6% 18.5%
Assets 1 4,700 4,578 6,557 11,079 13,568 14,247 15,215 16,270
Book Value Per Share 2 394.0 397.0 843.0 1,500 1,646 1,784 1,931 2,087
Cash Flow per Share 109.0 52.30 524.0 842.0 417.0 - - -
Capex 1 774 117 140 236 288 400 400 400
Capex / Sales 12.04% 2.78% 1.07% 1.34% 2.62% 4.21% 4% 3.81%
Announcement Date 2/12/20 2/10/21 2/10/22 2/10/23 2/9/24 - - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Mizuho Medy Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
MIZUHO MEDY CO.,LTD. Stock Mizuho Medy Co.,Ltd.
+5.25% 200M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.3B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 4595 Stock
  4. Financials Mizuho Medy Co.,Ltd.